Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 12, 2007, Pages 2324-2327

  Okutsu, Hiroko ^a   Noguchi, Yukiko ^a   Ohtake, Akiyoshi ^a   Suzuki, Masanori ^a   Sato, Shuichi ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Intravesical pressure elevation; Mouse; Muscarinic M3 receptor; Oral administration; Salivary secretion; Solifenacin

Indexed keywords

CARBACHOL; SOLIFENACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER PRESSURE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HYPERSALIVATION; INHIBITION KINETICS; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERACTIVE BLADDER; SALIVATION; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANESTHESIA; ANIMALS; BLOOD PRESSURE; CARBACHOL; INJECTIONS, INTRAVENOUS; MICE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; SALIVATION; TETRAHYDROISOQUINOLINES;

EID: 36849032249     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.2324     Document Type: Article

References (24)

1. Wang P., Luthin G. R., Ruggieri M. R., J. Pharmacol. Exp. Ther., 273, 959-966 (1995).
2. Tong Y. C., Hung Y. C., Lin S. N., Cheng J. T., J. Auton. Pharmacol., 17, 21-25 (1997).
3. Matsui M., Motomura D., Karasawa H., Fujikawa T., Jiang J., Komiya Y., Takahashi S., Taketo M. M., Proc. Natl. Acad. Sci. U.S.A., 97, 9579-9584 (2000).
4. Chess-Williams R., Chapple C. R., Yamanishi T., Yasuda K., Sellers D. J., J. Auton. Pharmacol., 21, 243-248 (2001).
5. Andersson K. E., Yoshida M., Eur. Urol., 43, 1-5 (2003).
6. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., Urology, 57, 414-421 (2001).
7. Diokno A. C., Appell R. A., Sand P. K., Dmochowski R. R., Gburek B. M., Klimberg I. W., Kell S. H., Mayo. Clin. Proc., 78, 687-695 (2003).
8. Chapple C., Steers W., Norton P., Millard R., Kralidis G., Glavind K., Abrams P., B. J. U. Int., 95, 993-1001 (2005).
9. Zinner N., Gittelman M., Harris R., Susset J., Kanellos A., Auerbach S., J. Urol., 171, 2311-2315 (2004).
10. Versi E., Appell R., Mobley D., Patton W., Saltzstein D., Obstet. Gynecol., 95, 718-721 (2000).
11. Davila G. W., Strarkman J. S., Dmochowski R. R., Urol. Clin. North Am., 33, 455-463 (2006).
12. Ikeda K., Kobayashi S., Suzuki M., Miyata K., Takeuchi M., Yamada T., Honda K., Naunyn-Schmiedeberg's Arch. Pharmacol., 366, 97-103 (2002).
13. Kobayashi S., Ikeda K., Miyata K., Life Sci., 74, 843-853 (2004).
14. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., Sasamata M., Eur. J. Pharmacol., 492, 243-250 (2004).
15. Reid L., http://www.fda.gov/cder/foi/nda/2004/21-518_VESIcare_pharmr.pdf, FDA Website.
16. Oki T., Sato S., Miyata K., Yamada S., Br. J. Pharmacol., 145, 219-227 (2005).
17. Oki T., Takeuchi C., Yamada S., Biol. Pharm. Bull., 29, 1397-1400 (2006).
18. Bymaster F. P., Carter P. A., Yamada M., Gomeza J., Wess J., Hamilton S. E., Nathanson N. M., McKinzie D. L., Felder C. C., Eur. J. Neurosci., 17, 1403-1410 (2003).
19. Gautam D., Heard T. S., Cui Y., Miller G., Bloodworth L., Wess J., Mol. Pharmacol., 66, 260-267 (2004).
20. Nakamura T., Matsui M., Uchida K., Futatsugi A., Kusakawa S., Matsumoto N., Nakamura K., Manabe T., Taketo M. M., Mikoshiba K., J. Physiol., 558, 561-575 (2004).
21. Kenakin T., Nat. Rev. Drug Discov., 2, 429-438 (2003).
22. Levin R. M., Ruggieri M. R., Lee W., Wein A. J., J. Urol., 139, 1347-1349 (1988).
23. Witt-Enderby P. A., Yamamura H. I., Halonen M., Lai J., Palmer J. D., Bloom J. W., Mol. Pharmacol., 47, 485-490 (1995).
24. Cardozo L., Lisec M., Millard R., Van Vierssen Trip O., Kuzmin I., Drogendijk T. E., Huang M., Ridder A. M., J. Urol., 172, 1919-1924 (2004)